Last reviewed · How we verify
ODM-203 (Period 1)
ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.
ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain. Used for Huntington's disease.
At a glance
| Generic name | ODM-203 (Period 1) |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | PDE10A inhibitor |
| Target | PDE10A (phosphodiesterase 10A) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
PDE10A is predominantly expressed in medium spiny neurons of the striatum. By inhibiting PDE10A, ODM-203 elevates cAMP and cGMP levels, modulating dopaminergic and glutamatergic neurotransmission. This mechanism is hypothesized to correct imbalances in basal ganglia signaling relevant to movement disorders.
Approved indications
- Huntington's disease
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ODM-203 (Period 1) CI brief — competitive landscape report
- ODM-203 (Period 1) updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI